The Japanese Patent Office has signalled its intention to grant patent protection for bioAffinity Technologies’ noninvasive lung cancer detection technology, expanding the company’s intellectual property coverage in Asia.
Key Investor Takeaways
- bioAffinity Technologies (NASDAQ:BIAF) has received a Japanese patent allowance covering its CyPath Lung diagnostic method and AI-built algorithm.
- The anticipated patent would become the company’s fifth Asian patent protecting its early lung cancer test and its first in Japan.
- The intellectual property portfolio currently includes 22 granted patents and 36 pending applications covering diagnostic technologies and cancer therapeutics.
- CyPath Lung demonstrated 92% sensitivity and 99% negative predictive value in a published clinical trial involving high-risk patients with small indeterminate lung nodules.
- Formal patent issuance remains subject to payment of the applicable fee, while the announcement provides no new revenue or commercialization forecasts.
Why BIAF Stock Is in Focus
bioAffinity Technologies has received a Notice of Allowance from the Japan Patent Office for its patent application titled “Detection of Early-Stage Lung Cancer in Sputum Using Automated Flow Cytometry and Machine Learning.”
The application covers a method of predicting the likelihood of lung cancer using the company’s CyPath Lung diagnostic platform, which combines automated flow cytometry with an artificial intelligence-based algorithm.
The allowance represents a further expansion of the company’s international patent protection, complementing existing coverage in China and Hong Kong.
CyPath Lung uses sputum samples that patients can collect at home to identify cellular indicators associated with lung cancer. Its technology incorporates a fluorescent porphyrin that is preferentially absorbed by cancer and cancer-related cells.
In a published clinical trial involving high-risk patients with indeterminate lung nodules smaller than 20 millimetres, CyPath Lung demonstrated 92% sensitivity, 87% specificity and 88% accuracy. The test also achieved a 99% negative predictive value, indicating its potential usefulness in helping physicians assess lung cancer risk.
The test is currently marketed as a Laboratory Developed Test through bioAffinity’s subsidiary, Precision Pathology Laboratory Services.
It is intended to support clinical decision-making alongside other findings rather than serve as a standalone diagnostic tool.
Why This Matters for Investors
The Japanese patent allowance could strengthen bioAffinity Technologies’ competitive positioning by extending legal protection for the technology underlying its principal diagnostic product.
For a biotechnology company developing proprietary diagnostic platforms, international intellectual property coverage may be important when evaluating future commercialization opportunities, partnerships and market expansion.
The development is particularly relevant because the proposed patent protects the combination of automated cellular analysis and machine learning used to assess lung cancer risk.
This protection could help differentiate CyPath Lung from competing diagnostic approaches and support the company’s longer-term strategy of establishing its technology across multiple geographic markets.
The reported clinical performance also provides context for the product’s potential role in evaluating patients with uncertain lung nodules. Its high negative predictive value suggests the test may help physicians assess whether additional invasive procedures are warranted, although results must be interpreted alongside other clinical information.
However, the Japanese patent allowance is an intellectual property milestone rather than a new regulatory approval or commercial agreement.
The announcement does not establish additional sales, reimbursement arrangements or a timeline for entering the Japanese diagnostic market.
Consequently, its immediate significance lies primarily in strengthening the company’s technology protection rather than demonstrating a measurable improvement in financial performance.
What to Watch Next
Investors should monitor the formal issuance of the Japanese patent following payment of the required fee, as well as decisions on the company’s remaining patent applications.
Additional intellectual property approvals could further expand protection for CyPath Lung across international markets.
Commercial developments will also remain important, particularly evidence of broader physician adoption, diagnostic testing demand and any future international commercialization arrangements.
For bioAffinity Technologies, the next significant question is whether its expanding patent portfolio can support measurable commercial progress for CyPath Lung.